BioCentury
ARTICLE | Regulation

Unleashing China's innovators

How China FDA reforms may unleash development of innovative drugs

October 19, 2015 7:00 AM UTC

An ambitious slate of reforms proposed by China's State Council could at last relieve the regulatory bottlenecks that have long hobbled development of innovative drugs in and for China by domestic and multinational pharmas alike.

If coupled with pricing and reimbursement reforms proposed earlier this year, the effect on access to innovative medicines would be profound, according to BioCentury's reporting with lawyers and principals at international management consultancies who practice in China, and domestic R&D executives. ...